BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

375 related articles for article (PubMed ID: 32420775)

  • 1. Venetoclax is safe and efficacious in relapsed/refractory AML.
    Ganzel C; Ram R; Gural A; Wolach O; Gino-Moor S; Vainstein V; Nachmias B; Apel A; Koren-Michowitz M; Pasvolsky O; Yerushalmi R; Danylesko I; Cohen Y; Peretz G; Moshe Y; Zektser M; Yeganeh S; Rowe JM; Ofran Y
    Leuk Lymphoma; 2020 Sep; 61(9):2221-2225. PubMed ID: 32420775
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 10-day decitabine with venetoclax for newly diagnosed intensive chemotherapy ineligible, and relapsed or refractory acute myeloid leukaemia: a single-centre, phase 2 trial.
    DiNardo CD; Maiti A; Rausch CR; Pemmaraju N; Naqvi K; Daver NG; Kadia TM; Borthakur G; Ohanian M; Alvarado Y; Issa GC; Montalban-Bravo G; Short NJ; Yilmaz M; Bose P; Jabbour EJ; Takahashi K; Burger JA; Garcia-Manero G; Jain N; Kornblau SM; Thompson PA; Estrov Z; Masarova L; Sasaki K; Verstovsek S; Ferrajoli A; Weirda WG; Wang SA; Konoplev S; Chen Z; Pierce SA; Ning J; Qiao W; Ravandi F; Andreeff M; Welch JS; Kantarjian HM; Konopleva MY
    Lancet Haematol; 2020 Oct; 7(10):e724-e736. PubMed ID: 32896301
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Venetoclax in combination with hypomethylating agents or low dose cytarabine for relapsed and refractory acute myeloid leukemia.
    Graveno ME; Carulli A; Freyer CW; Mangan BL; Nietupski R; Loren AW; Frey NV; Porter DL; Gill SI; Hexner EO; Luger SM; Martin ME; McCurdy SR; Perl AE; Babushok DV; Pratz KW
    Leuk Lymphoma; 2022 Jul; 63(7):1645-1650. PubMed ID: 35259056
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Venetoclax in combination with cytarabine with or without idarubicin in children with relapsed or refractory acute myeloid leukaemia: a phase 1, dose-escalation study.
    Karol SE; Alexander TB; Budhraja A; Pounds SB; Canavera K; Wang L; Wolf J; Klco JM; Mead PE; Das Gupta S; Kim SY; Salem AH; Palenski T; Lacayo NJ; Pui CH; Opferman JT; Rubnitz JE
    Lancet Oncol; 2020 Apr; 21(4):551-560. PubMed ID: 32171069
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Venetoclax combinations induce high response rates in newly diagnosed acute myeloid leukemia patients ineligible for intensive chemotherapy in routine practice.
    Apel A; Moshe Y; Ofran Y; Gural A; Wolach O; Ganzel C; Canaani J; Zektser M; Duek A; Stemer G; Hellman I; Basood M; Frisch A; Leibovitch C; Koren-Michowitz M
    Am J Hematol; 2021 Jul; 96(7):790-795. PubMed ID: 33836555
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Venetoclax plus LDAC for newly diagnosed AML ineligible for intensive chemotherapy: a phase 3 randomized placebo-controlled trial.
    Wei AH; Montesinos P; Ivanov V; DiNardo CD; Novak J; Laribi K; Kim I; Stevens DA; Fiedler W; Pagoni M; Samoilova O; Hu Y; Anagnostopoulos A; Bergeron J; Hou JZ; Murthy V; Yamauchi T; McDonald A; Chyla B; Gopalakrishnan S; Jiang Q; Mendes W; Hayslip J; Panayiotidis P
    Blood; 2020 Jun; 135(24):2137-2145. PubMed ID: 32219442
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Venetoclax Combined With Low-Dose Cytarabine for Previously Untreated Patients With Acute Myeloid Leukemia: Results From a Phase Ib/II Study.
    Wei AH; Strickland SA; Hou JZ; Fiedler W; Lin TL; Walter RB; Enjeti A; Tiong IS; Savona M; Lee S; Chyla B; Popovic R; Salem AH; Agarwal S; Xu T; Fakouhi KM; Humerickhouse R; Hong WJ; Hayslip J; Roboz GJ
    J Clin Oncol; 2019 May; 37(15):1277-1284. PubMed ID: 30892988
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Chemotherapy and Venetoclax in Elderly Acute Myeloid Leukemia Trial (CAVEAT): A Phase Ib Dose-Escalation Study of Venetoclax Combined With Modified Intensive Chemotherapy.
    Chua CC; Roberts AW; Reynolds J; Fong CY; Ting SB; Salmon JM; MacRaild S; Ivey A; Tiong IS; Fleming S; Brown FC; Loo S; Majewski IJ; Bohlander SK; Wei AH
    J Clin Oncol; 2020 Oct; 38(30):3506-3517. PubMed ID: 32687450
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Venetoclax with low-dose cytarabine for patients with untreated acute myeloid leukemia ineligible for intensive chemotherapy: results from the Chinese cohort of a phase three randomized placebo-controlled trial].
    Hu Y; Jin J; Zhang Y; Hu JD; Li JM; Wei XD; Gao SJ; Zha JH; Jiang Q; Wu J; Mendes W; Wei AH; Wang JX
    Zhonghua Xue Ye Xue Za Zhi; 2021 Apr; 42(4):288-294. PubMed ID: 33979972
    [No Abstract]   [Full Text] [Related]  

  • 10. Venetoclax combination therapy in relapsed/refractory acute myeloid leukemia: A single institution experience.
    Gaut D; Burkenroad A; Duong T; Feammelli J; Sasine J; Schiller G
    Leuk Res; 2020 Mar; 90():106314. PubMed ID: 32035355
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Venetoclax in patients with acute myeloid leukemia refractory to hypomethylating agents-a multicenter historical prospective study.
    Ram R; Amit O; Zuckerman T; Gurion R; Raanani P; Bar-On Y; Avivi I; Wolach O
    Ann Hematol; 2019 Aug; 98(8):1927-1932. PubMed ID: 31187237
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical and molecular predictors of response and survival following venetoclax therapy in relapsed/refractory AML.
    Stahl M; Menghrajani K; Derkach A; Chan A; Xiao W; Glass J; King AC; Daniyan AF; Famulare C; Cuello BM; Horvat TZ; Abdel-Wahab O; Levine RL; Viny AD; Stein EM; Cai SF; Roshal M; Tallman MS; Goldberg AD
    Blood Adv; 2021 Mar; 5(5):1552-1564. PubMed ID: 33687434
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Short-term efficacy of venetoclax combined with azacitidine in acute myeloid leukemia: a single-institution experience].
    Yu WJ; Jia JS; Wang J; Tang FF; Gong LZ; Liu XH; Zhu XL; Zhao XS; Huang XJ; Jiang H
    Zhonghua Xue Ye Xue Za Zhi; 2022 Feb; 43(2):134-140. PubMed ID: 35381674
    [No Abstract]   [Full Text] [Related]  

  • 14. Real world results of venetoclax combined with hypomethylating agents in relapsed/refractory AML.
    Ucar MA; Ozet G; Koyuncu MB; Sonmez M; Akidan O; Ayli M; Yildirim M; Pehlivan M; Akkurd DM; Sahin H; Guvenc B; Okan V; Tiftik EN; Akdeniz A; Dincyurek HD; Gunes AK; Dagdas S; Acar HI; Ucar HK; Tombak A
    Eur Rev Med Pharmacol Sci; 2021 Nov; 25(21):6557-6565. PubMed ID: 34787859
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical experience with venetoclax in patients with newly diagnosed, relapsed, or refractory acute myeloid leukemia.
    Fleischmann M; Scholl S; Frietsch JJ; Hilgendorf I; Schrenk K; Hammersen J; Prims F; Thiede C; Hochhaus A; Schnetzke U
    J Cancer Res Clin Oncol; 2022 Nov; 148(11):3191-3202. PubMed ID: 35099591
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Phase II Study of Azacitidine, Venetoclax, and Trametinib in Relapsed or Refractory Acute Myeloid Leukemia Harboring RAS Pathway-Activating Mutations.
    Desikan SP; Ravandi F; Pemmaraju N; Konopleva M; Loghavi S; Jabbour EJ; Daver N; Jain N; Chien KS; Maiti A; Montalban-Bravo G; Kadia TM; Macaron W; DeLumpa R; Kwari M; Borthakur G; Short NJ
    Acta Haematol; 2022; 145(5):529-536. PubMed ID: 35717939
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Venetoclax and hypomethylating agents in acute myeloid leukemia: Mayo Clinic series on 86 patients.
    Morsia E; McCullough K; Joshi M; Cook J; Alkhateeb HB; Al-Kali A; Begna K; Elliott M; Hogan W; Litzow M; Shah M; Pardanani A; Patnaik M; Tefferi A; Gangat N
    Am J Hematol; 2020 Dec; 95(12):1511-1521. PubMed ID: 32833294
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Real-life Turkish Experience of Venetoclax Treatment in High-risk Myelodysplastic Syndrome and Acute Myeloid Leukemia.
    Gemici A; Ozkalemkas F; Dogu MH; Tekinalp A; Alacacioglu I; Guney T; Ince I; Geduk A; Cagliyan GA; Maral S; Serin I; Gunduz E; Karakus V; Bekoz HS; Eren R; Pinar IE; Gunes AK; Sargın FD; Sevindik OG
    Clin Lymphoma Myeloma Leuk; 2021 Aug; 21(8):e686-e692. PubMed ID: 34059487
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Gilteritinib in combination with venetoclax, low-dose cytarabine and actinomycin D for relapsed or refractory FLT3-mutated acute myeloid leukaemia.
    Zucenka A; Griskevicius L
    Br J Haematol; 2024 Apr; 204(4):1227-1231. PubMed ID: 38291741
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Clinical Observation of Venetoclax Combined with Demethylating Agents on the Treatment of Relapsed/Refractory Acute Myeloid Leukemia].
    Wang Y; Huang SL; Zhang XX; Bian MR; Lin GQ; Si YJ; Zhang B; Wan Y; Wang L; Zhang YM
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2023 Apr; 31(2):327-332. PubMed ID: 37096501
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.